Follistatin-344 is a naturally occurring protein that blocks myostatin and activin A — two molecular brakes on muscle growth — and is being explored, mostly through gene therapy and self-reported injectable use, as a tool for increasing muscle mass and countering muscle-wasting diseases.
What it does
Myostatin (also called GDF-8) is a signaling protein that your body uses to limit how much muscle you can build. Follistatin-344 binds myostatin with high affinity and prevents it from docking onto its receptor — ActRIIB (activin receptor type IIB) — on muscle cells. With that brake removed, satellite cells (the muscle's stem-cell pool) activate more readily, protein synthesis increases, and muscle hypertrophy (growth of individual muscle fibers) can proceed with less resistance Ahmad 2025. The effect mirrors what researchers see in myostatin-null animals, which develop dramatically oversized musculature Joonho 2025.
Follistatin-344 also neutralizes activin A, a related signaling molecule with overlapping anti-muscle effects. Activin A normally stimulates FSH (follicle-stimulating hormone) release from the pituitary, so follistatin's inhibition of activin A suppresses FSH — a side effect with real reproductive implications Dorota 2021. The muscle-loss pathways that follistatin targets also appear in serious disease states: cancer cachexia (muscle wasting driven by tumor signaling), sarcopenia (age-related muscle loss), and neuromuscular diseases all involve dysregulated myostatin and activin signaling Yichi 2024 Ahmad 2025.
The most rigorous clinical data on follistatin-344 comes from AAV (adeno-associated virus) gene therapy trials — where a viral vector delivers the gene for FS-344 directly into muscle — not from injectable follistatin protein. That distinction matters enormously when evaluating the human evidence, because the pharmacology of a viral gene depot is fundamentally different from a subcutaneous protein injection with a ~6-hour half-life.
What the evidence shows
Muscular dystrophy and neuromuscular disease Small Phase 1/2a human trial (gene therapy, not injectable protein); promising but not definitive
The Mendell 2015 Phase 1/2a trial used an AAV vector carrying the FS-344 gene injected directly into the biceps of Becker muscular dystrophy (BMD) patients. Participants showed modest improvements in a six-minute walk test and some increase in lean muscle volume. Critically, this was intramuscular gene delivery — the muscle produced follistatin locally — not a circulating injectable protein. Extrapolating these results to self-administered subcutaneous protein injections is a significant logical leap. Separate work in SMA (spinal muscular atrophy) patients confirmed that myostatin-pathway dysregulation is measurable in human neuromuscular disease, providing biological rationale for targeting this pathway Laurane 2024.
Sarcopenia (age-related muscle loss) Solid mechanistic and rodent evidence; human data indirect and preliminary
Sarcopenia involves elevated myostatin signaling relative to anabolic signals, and follistatin levels decline with age — making the myostatin/follistatin ratio a plausible driver of muscle loss Dorota 2021 Liang-Kung 2024. Myostatin inhibition in aged rodents consistently restores muscle mass and function Ahmad 2025. Human interventional data using follistatin-344 specifically is absent; existing human trials in sarcopenia focus on upstream interventions like amino acid supplementation NCT05093218 or other modulators NCT06721910 NCT04112875, not follistatin protein. The biological rationale is sound; the clinical evidence for follistatin-344 as an injectable is not yet there.
Athletic muscle enhancement No controlled human trial data; anecdotal use; sports anti-doping bodies are actively tracking it
Follistatin-344 is used in self-reported athletic contexts to increase lean mass, based on the same myostatin-inhibition mechanism. No randomized controlled trial has tested injectable follistatin protein in healthy athletes or bodybuilders. Sports anti-doping researchers have begun developing detection methods for myostatin-inhibitory peptides including follistatin analogs, reflecting real-world use Katja 2023. Any performance claims in this context rest on mechanism and anecdote, not controlled evidence. The rapid muscle gain that the mechanism predicts also raises a specific structural risk: tendons adapt more slowly than muscle, increasing injury potential when muscle strength outpaces connective tissue capacity.
Metabolic and inflammatory muscle wasting Rodent and in vitro evidence; no human trials with follistatin-344 directly
Myostatin signaling is upregulated in diabetic muscle atrophy and inflammatory conditions including IBD (inflammatory bowel disease), suggesting a mechanistic role for follistatin Sarai 2025 Dorota 2021. Cancer cachexia involves a well-characterized molecular cascade that converges on ActRIIB — the same receptor follistatin blocks Yichi 2024. Follistatin's inhibition of activin A is also relevant here, since activin A contributes to muscle wasting in chronic disease Konstantinos 2024. None of these lines of evidence constitute clinical trials of follistatin-344 protein itself; they establish the pathway's relevance, not the compound's safety or efficacy in humans.
How it's used
In the one published human gene therapy trial (Mendell 2015), FS-344 was delivered via direct intramuscular injection of an AAV vector — a one-time procedure, not a repeating dosing schedule. For injectable follistatin-344 protein, there is no peer-reviewed clinical dosing protocol. In self-reported protocols circulating online, doses range from 100 mcg subcutaneously every other day (lower end) to 200–300 mcg every other day (mid-range) and up to 500 mcg every other day (higher end). The protein half-life is approximately 6 hours, which is why every-other-day dosing is the common convention rather than daily. Timing relative to meals or training has not been studied in controlled settings. IM (intramuscular) injection is also reported. These figures come from self-reported use, not clinical trials.
Side effects and safety
Reported mild effects include injection site reactions and transient fatigue. Moderate effects reported in self-use contexts include joint pain, muscle cramping, and headache — plausibly related to rapid shifts in muscle-tendon load distribution. The most serious theoretical risk is tumor promotion: myostatin and activin A both have tumor-suppressive properties in some cancers, and sustained suppression of these pathways in someone with an undiagnosed malignancy could accelerate tumor growth Ahmad 2025. This makes active malignancy an absolute contraindication. Activin A suppression also meaningfully reduces FSH, which can impair fertility and disrupt reproductive hormone balance — a concern for anyone planning to conceive Dorota 2021. Rapid muscle hypertrophy outpacing tendon adaptation is a structural risk specific to effective myostatin inhibition. Long-term safety data for injectable follistatin-344 protein in humans simply does not exist — the compound has not been studied in this form in any published long-term human trial.
Bottom line
The biological rationale for follistatin-344 is solid — blocking myostatin does increase muscle mass, and the pathway is genuinely relevant to muscle disease and aging — but the human clinical evidence is almost entirely from gene therapy, not injectable protein, and cannot be directly applied to subcutaneous dosing. Anyone considering it should weigh a real mechanistic basis against essentially zero controlled human safety data for the injectable form, meaningful reproductive and oncological risks, and the structural hazard of muscle growing faster than tendons can handle.